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Background
Interactions between endogenous factors, 
e.g., gene allelic variants, and exogenous 
factors, e.g., exposure to specific environ-
ments, can be reasonably suspected as the 
cause of the most common chronic com-
munication disorders. However, the elucida-
tion of genetic factors and their interactions 
with non-genetic factors in behavioral 
diseases has been challenged. To date, two 
main strategies have been used for the iden-
tification of genes for diseases of unknown 
molecular etiology. Over two decades, link-
age analysis and positional cloning of the 
disease gene were effective in the identifica-
tion of genes for Mendelian or monogenic 
single-gene disorders (Botstein and Risch, 
2003; McKusick, 2007). The methodological 
and statistical threshold criteria, applied for 
linkage analysis in families, provides robust 
evidence for identification of chromosomal 
locus and the gene mutation characterized 
by high penetrance. Among common neu-
ropsychiatric diseases, the approach was 
successful in the identification of genes 
for familial early onset Alzheimer’s disease 
(AD) carrying autosomal-dominant muta-
tions in PSEN1, PSEN2 genes (Rogaev et al., 
1995; Sherrington et al., 1995). Another 
genetic approach, genome-wide associa-
tion (GWA), or direct genetic association 
analysis in candidate-genes, employs rela-
tively common genetic variations across the 
genome or in selected genes for compara-
tive analysis in case–control groups. GWA 
has been applied for hundreds phenotype 
traits, including neuropsychiatric conditions 
(Wellcome Trust Case Control Consortium, 
2007; Donnelly, 2008). The genetic associa-
tion methodology generated much more 
controversial data in interpretation (Pearson 
and Manolio, 2008). In most cases, the GWA 
studies identified only a minor proportion 
of genetic contribution to common ill-
nesses with little medical diagnostic value. 
Nonetheless, the genetic association method 
revealed some convincing data. For exam-
ple, as confirmed in numerous studies, ApoE 
ε4 allelic isoform is a   common risk factor 
for AD in ethnic groups of Caucasian and 
Asian origin. Analysis of two large Caucasian 
cohorts stratified by age showed that the 
ApoE-genotype dependent lifetime risks 
for AD are similar to those of Mendelian-
disease genes with major risk effect (Genin 
et al., 2011). Unlike AD, however, no mutant 
gene convincingly inherited as a Mendelian 
trait has yet been described for schizophre-
nia and affective disorders, despite the fact 
that many mutigenerational pedigrees are 
available. GWA employs relatively common 
single-nucleotide polymorphisms (SNPs) 
across the genome. The recently emerged 
concept that rare genetic variations, rather 
than common population variations, under-
lie common diseases challenges the standard 
genetic association approach in neuropsy-
chiatric genetics.
rare and non-coding variations
Indeed, rare copy-number variations 
(CNVs) in a few chromosomal loci have 
been found in a small proportion of schizo-
phrenia samples (Karayiorgou et al., 1995; 
International Schizophrenia Consortium, 
2008; Mulle et al., 2010; Vacic et al., 2011). 
Among numerous genes implicated for 
schizophrenia, a few candidate-genes, such 
as DISC or NPAS3, with disrupted struc-
ture due to chromosomal translocations in 
single patients, can be noted (Millar et al., 
2000; Kamnasaran et al., 2003).
Emerging new generation sequenc-
ing technology, termed deep or massively 
parallel sequencing (MPS), may transform 
the field. Direct sequencing of all genes, or 
preferably whole-genome sequences, will 
provide complete genetic information of 
the patient. However, from our current 
knowledge on population genetic variabil-
ity, we can expect >3.5 million SNPs and 
>1,000 CNVs of genomic sequences per 
individual in comparison to reference 
genome sequence. Thus, excluding genetic 
“background” and identification of disease-
related variations in the individual genomes 
remains a challenge in study of behavior 
diseases.
Currently available MPS platforms (e.g., 
Illumina or Complete Genomics) produce 
biases to different types of errors in nucleo-
tide sequences (Lam et al., 2011). Another 
challenge is a biological interpretation of 
genetic variations found via direct genome 
sequencing analysis. Application of high-
throughput functional assays in cellular 
models and in animals testing the biologi-
cal significance of suspected mutations or 
polymorphisms in selected genes may be 
one possible solution.
De novo mutations
Another recently proposed approach is the 
identification of genes via analysis of de 
novo mutations in exome. Despite reduced 
reproductive fitness, the rate of incidence 
for schizophrenia and autism is relatively 
stable (0.4–1%) in worldwide popula-
tions (Bassett et al., 1996; Saha et al., 2005; 
Center for Disease Control and Prevention, 
2009). The Hardy–Weinberg concept could 
explain, in part, the long-term maintenance 
of recessive mutant alleles in populations. 
Another explanation is that spontaneous 
de novo mutation process contributes to 
the relatively frequent population occur-
rence of schizophrenia and autism. In this 
event, we may anticipate the increased risk 
for disease with increased parental age due 
to age-dependent increased mutation fre-
quency in gametogenesis. Indeed, the effect 
of paternal (but not maternal) age on the 
risk for schizophrenia has been reported. 
Meta-analysis studies suggest that there is 
an increased relative risk for schizophre-
nia from 1.84 to 4.62 in children of fathers 
with an older age of fatherhood (Hubert 
et al., 2011). Instead of searching for large 
families and pedigrees, the small nuclear 
families with one proband and no other 
schizophrenia cases in the family history 
are a subject of interest. Recently, puta-
tive causative de novo mutations were 
found in an analysis of genomic exomes 
of 4 of 20 analyzed probands with autism 
(O’Roak et al., 2011). Two studies employed 
sequencing of exomes for schizophrenia. 
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are targets for the epigenomic regulations 
are under pressure of negative selection. 
These regions are characterized by a rela-
tive deficiency in SNPs (Tolstorukov et al., 
2011). On the other hand, the mutations 
in these regions, if they occur, may directly 
affect the chromatin structure or DNA 
methylation, thereby affecting the capac-
ity of these regions for either epigenomic 
stress-induced or cell specific (e.g., neu-
ronal) regulations.
I believe it would be reasonable to 
hypothesize that the genetic–epigenomic 
interactions (GEI) play a significant role 
in common human illness, particularly in 
behavioral diseases, including major psy-
chiatric diseases, such as schizophrenia, 
affective disorders, autism, or even in age-
related dementias. Any SNP or structural 
genetic variation in cis-position located at 
a distant regulatory region or nearby gene 
only a small portion of the genome, <1%, is 
represented by exome, most of the sponta-
neous germline mutations must be located 
in non-coding genomic regions. Therefore, 
the complete genome sequencing in search 
of de novo mutations in neuropsychiatric 
diseases is a promising strategy. The search 
for mutations in sequences for enhanc-
ers, insulators, and repressors, which are 
often physically distant (e.g., >1 Mb) 
from the gene transcriptional start, along 
with 5′-and 3′-UTRs (untranslated gene 
regions) and promoter gene regions must 
be analyzed.
epigenomics
Unlike genetics, epigenomic variations are 
generally reversible alterations that can be 
identified by analysis of the state of DNA 
methylation or histone modifications spe-
cific for active and non-active chromatin 
(Park, 2008).
In summary, in 35 probands from fam-
ily trios, several different genes bearing 
de novo mutations were found. With one 
exception for a DGCR2 gene located on 
schizophrenia-associated 22q11.2 microde-
letion region, the mutant genes are not pre-
sented in putative schizophrenia-associated 
chromosomal loci or pathways predicted 
in previous studies (Girard et al., 2011; Xu 
et al., 2011). There was no match between 
the genes with de novo mutations found in 
independent families. Thus, the pathogenic 
significance of the identified mutations for 
schizophrenic trait must be further verified.
Estimates made from preliminary analy-
sis of parent–child genome sequences sug-
gest a rate of de novo spontaneous germline 
mutation ∼1.1 × 10−8 bp for human haploid 
genome (Roach et al., 2010). It would cor-
respond to ∼60–70 new mutations per dip-
loid genome in each individual, which are 
non-inherited from the parents. Because 
Figure 1 | epigenomic and genetic interactions in regulation of 
chromatin and gene activity underlying behavior traits. Genes can be 
regulated via genomic elements (enhancers, repressors, insulators) in 
tissue-specific manner. Epigenomic modification of chromatin in brain cells 
can be affected by programmed transformation, environmental factors, and 
genetic variations in the regulatory regions. Alteration of the transcription of 
the gene can also be caused by mutation in the regulatory elements without 
obvious changes in chromatin. Open or active chromatin structures are 
identified by the mapping of DNAse-hypersensitive sites and by Chip-seq 
technology, which tracks the genomic regions forming complexes with 
differentially modified histones (K) or the sequences binding with transcription 
regulatory proteins.
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variations in the same individual genomes 
can be detected by MPS using rapidly 
progressing methodologies for analysis of 
DNA methylation with single-nucleotide 
resolution, DNAse-I hypersensitive sites, 
or Chip-seq data for transcriptional start 
sites or transcriptional regulatory ele-
ments. For example, Chip-seq can track 
transcriptional start sites via detection of 
sites for histone H3 trimethylated at lysine 
4 (H3K4me3) and other transcriptional 
regulatory elements including enhanc-
ers enriched with histone H3 acetylated 
at lysine 27 (H3K27Ac) and histone H3 
monomethylated at lysine 4 (H3K4me1). 
DNAse-I hypersensitive sites (at least 
∼1–2% of genome) mark open or active 
chromatins associated with majority of 
regulatory and transcriptional start sites.
Beyond neuropsychiatric illnesses, I sug-
gest that GEIs may also underlie changes in 
non-pathogenic behavioral traits and that 
the interplay between genetic variations and 
epigenomic modifications could be identi-
fied through the study of non-conventional 
animal models. Genomic sequencing, cou-
pled with epigenomic studies, provides per-
spective in the identification of alterations 
in genome correlated with rapid behavior 
changes under certain selection process in 
rodents (e.g., in rats) or, in follow-up arti-
ficial selection in domesticated animals. 
Rapid changes in behavior, from native 
aggressive defending reaction to tolerant 
or even to “the man’s best friend” behav-
ior in Canidae species, can be achieved in 
just a few generations, as demonstrated in 
the domestication experiments of silver 
foxes selected for tameability (Spady and 
Ostrander, 2008; Trut et al., 2009; Parker 
et al., 2010). The patterns of genetic altera-
tions underlying changes in this behavior 
paradigm have yet to be identified. Perhaps 
it is not an exaggeration to speculate that 
elucidation of such a mechanism may also 
contribute to understanding the evolution 
of normal and abnormal social behavior in 
humans, and even of our own tolerance or 
intolerance of each other.
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can alter the constitutive or tissue-specific 
state of active chromatin and regulation 
of the gene (Figure 1). Certain epigenetic 
mutations can be silent, but will manifest 
due to programmed epigenomic transfor-
mations during development, the aging 
process, or triggered under specific con-
ditions, e.g., hypothalamus – axilatory 
mediated stress conditions, or exposure 
to infection or chemical compounds. We 
could speculate that the silent variations 
affecting the epigenomic state play a role 
in some psychiatric disorders with revers-
ible clinical manifestation (schizophrenia 
and bipolar disorder) or stress-induced and 
age-related diseases.
Despite the fact that the genetic role of 
schizophrenia is well-established, and that 
multiple informative schizophrenia families 
have been available for a long time, there 
is, as yet, no robust evidence for mutations 
in genes altering the protein structure in 
any significant number of schizophrenia 
cases as observed, e.g., in AD. Classical 
twin analysis showed that the contribution 
of non-genetic factors to schizophrenia is 
at least 50%. The number of autism spec-
trum disorder (ASD) cases continues to 
increase. Currently, ASD is diagnosed in 1 
of 110 children (Center for Disease Control 
and Prevention, 2009). The cause of the 
rising rate for ASD is unknown. Recent 
re-evaluation of large cohorts of twins also 
demonstrated that there is a significant role 
of non-genetic factors in ASDs, and up to 
37–38% of genetic factors in contrast to the 
previous conception of an ∼90% heritability 
in autism. A surprisingly significant role of 
shared twin environment, evidenced by high 
dizygotic twin concordance, was observed 
(Hallmayer et al., 2011). The hypothesis of 
GEI seems to be very relevant to ASD and 
schizophrenia.
Modified genomic DNA and chromatin 
complexes can be extracted from neuronal 
cells separately from glial cell popula-
tions from postmortem brain specimens 
(Matevossian and Akbarian, 2008). We can 
attempt to determine whether structural or 
single-nucleotide variations in individual 
genomes (genetic variations) correlate 
with individual variations in DNA meth-
ylation or methylation/acetylation histone 
modifications (epigenomic variations) in 
the same loci in neuronal cells. Genetic 
variations can be identified by whole-
genome MPS re-sequencing. Epigenomic 
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